Updates are available Correction dated 2023-02-15
Click to view Correction: https://doi.org/10.1007/s00401-023-02549-1
-
Authors
Boza-Serrano, Antonio https://orcid.org/0000-0003-2121-2486
Ruiz, Rocío
Sanchez-Varo, Raquel
García-Revilla, Juan
Yang, Yiyi
Jimenez-Ferrer, Itzia
Paulus, Agnes
Wennström, Malin
Vilalta, Anna
Allendorf, David
Davila, Jose Carlos
Stegmayr, John
Jiménez, Sebastian
Roca-Ceballos, Maria A.
Navarro-Garrido, Victoria
Swanberg, Maria
Hsieh, Christine L.
Real, Luis M.
Englund, Elisabet
Linse, Sara
Leffler, Hakon
Nilsson, Ulf J.
Brown, Guy C.
Gutierrez, Antonia
Vitorica, Javier
Venero, Jose Luis
Deierborg, Tomas
-
Funding
Funding for this research was provided by:
Vetenskapsrådet
Multipark
Swedish Alzheimer’s Foundation
Swedish Brain Foundation
Anna och Edwin Bergers Stiftelse
Gyllenstiernska Krapperup Foundation
the Royal Physiographic Society
Olle Engkvist Byggmästare Foundation
Wiberg Foundation
G&J Kock Foundation
Stohnes Foundation
Swedish Dementia Association and the Medical Faculty at Lund University
MINECO/FEDER (SAF2015-64171R)
FIS (FIS PI12/O1431, FIS PI15/00796)
FEDER funds from European Union, through grants (PI12/01439, PI15/00957)
FEDER (PI12/01431, PI15/00796)
Proyecto Excelencia Junta Andalucia (CTS-2035)
Innovative Medicines Initiative 2 Joint Undertaking under grant agreement (No 115976 (PHAGO))
Knut and Alice Wallenberg Foundation ((KAW 2013.0022))
Swedish Research Council (621-2012-2978)
- License Information
-
More Information
Article History
Received: 23 November 2018
Revised: 12 April 2019
Accepted: 12 April 2019
First Online: 20 April 2019
Change Date: 15 February 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00401-023-02549-1
Compliance with ethical standards
:
: Ulf J. Nilsson and Hakon Leffler are shareholders in Galecto Biotech AB, Sweden, which develops galectin inhibitors towards clinical use.
